Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03957759
Other study ID # 01-8/464-14
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 20, 2019
Est. completion date August 8, 2021

Study information

Verified date November 2022
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel.


Description:

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel. After baseline evaluation at 760 m, patients will travel by bus within 3-5 h to the Tuja Ashu high altitude clinic at 3'100 m and stay there for 2 days. During this period, participants will perform SSM. They are instructed to report to study personnel if they fulfill predefined criteria for impeding altitude-related illness. A planned interim analysis will be performed after the first year of the study or after completion of study by 80 participants, whichever comes first to allow any necessary adaptations of the sample size or terminate the study early for futility or high accuracy of the index test.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date August 8, 2021
Est. primary completion date August 8, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion criteria - Male and female patients, age 18-75 yrs. - COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92%, PaCO2 <6 kPa at 760 m. - Born, raised and currently living at low altitude (<800 m). - Written informed consent. Exclusion criteria - COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1 <40% predicted; oxygen saturation on room air <92% or hypercapnia at 760 m). - Other lung disease or disorder of control of breathing - Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke, internal, neurologic, rheumatologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Structured self-monitoring during an altitude ascent and stay at high altitude
Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).

Locations

Country Name City State
Kyrgyzstan National Center of Cardiology and Internal Medicine Bishkek

Sponsors (2)

Lead Sponsor Collaborator
University of Zurich National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

Country where clinical trial is conducted

Kyrgyzstan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accurarcy measures of structured self-monitoring Diagnostic performance includes sensitivity, specificity, positive and negative predictive values, and receiver operator curve area under the the curve. The diagnostic performance will be compared statistically using c-statistics against the reference test. Reference test will be the occurence of altitude-related illness defined as the following:
AMS defined by the Lake Louise questionnaire score or with AMSc score
severe hypoxemia (SpO2 <80% at rest >30 min; or SpO2 <75% at rest >15 min;
intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators.
dyspnea or discomfort at rest requiring treatment with oxygen
chest pain or ECG signs of cardiac ischemia
severe hypertension: systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg
new onset neurologic impairment
Any condition that requires study withdrawal according to the decision of the independent physician
Day 1 to 3 at 3100m
Secondary Acute mountain sickness severity assessed by the Lake Louise score The severity of acute mountain sickness will be assessed by the Lake Louise questionnaire. The severity will be calculated when the presence of headache and at least one of the following symptoms is present: gastrointestinal upset, fatigue or weakness and dizziness or lightheadedness. Each of the four questions is asked with the corresponding 0 to 3 rating of the response (0 = Not present, 1 = mild, 2 = moderate, 3 = severe). The sum of the responses on these questions is then calculated, resulting in the AMS severity. Day 1 to 3 at 3100m
Secondary Altitude-related illness, incidence Incidence of ARI during the stay at 3100 m.
ARI is defined as the following:
AMS defined by the Lake Louise questionnaire score or with AMSc score
severe hypoxemia (SpO2 <80% at rest >30 min; or SpO2 <75% at rest >15 min;
intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators.
dyspnea or discomfort at rest requiring treatment with oxygen
chest pain or ECG signs of cardiac ischemia
severe hypertension: systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg
new onset neurologic impairment
Any condition that requires study withdrawal according to the decision of the independent physician
Day 1 to 3 at 3100m
Secondary Spirometric measurement of forced expiratory volume in one second Altitude-induced change in the forced expiratory volume in one between 760 and 3100m Day 2 at 760 and 3100m
Secondary Arterial partial pressure of oxygen Altitude-induced change in arterial partial pressure of oxygen assessed by arterial blood gas puncture at 760 and 3100m Day 2 at 760 and 3100m
Secondary Six-minute walk distance in meters Altitude-induced change in the six-minute walk distance assessed by the six-minute walk test performed at 760 and 3100m Day 2 at 760 and 3100m
Secondary Changes in ST-Segment of the ECG during ergometry Altitude-induced change in the ST-Segment of the ECG assessed during a maximal ergometry test performed at 760 and 3100m Day 1 at 760 and 3100m
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy